UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 16, 2016

DELMAR PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

Nevada	**000-54801**	**99-0360497**
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)

Suite 720-999 West Broadway
Vancouver, British Columbia
Canada V5Z 1K5
(Address of principal executive offices) (zip code)

(604) 629-5989
(Registrant's telephone number, including area code)

Copies to:
Gregory Sichenzia, Esq.
Jeff Cahlon, Esq.
Sichenzia Ross Friedman Ference LLP
61 Broadway
New York, New York 10006
Phone: (212) 930-9700
Fax: (212) 930-9725

(Former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition.

On February 16, 2016, DelMar Pharmaceuticals, Inc. (the "Company") issued a press release announcing its financial results for the period ended December 31, 2015 and certain other information. The press release is attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 2.02 of Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 8.01 Other Events.

On February 17, 2016, the Company made a presentation at its earnings call, a copy of which is attached as Exhibit 99.2.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1	Press Release.
99.2	Presentation.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DELMAR PHARMACEUTICALS, INC.

Dated: February 18, 2016

By: /s/ Jeffrey Bacha
Name: Jeffrey Bacha
Title: Chief Executive Officer

Exhibit 99.1

DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2016 Financial Results and Corporate Update

- Business update conference call and webcast on February 17, 2016 at 5:00 PM EST -

VANCOUVER, British Columbia and MENLO PARK, Calif., February 16, 2016 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced its financial results for the second quarter of the 2016 fiscal year ending December 31, 2015. The Company also highlighted recent corporate and clinical achievements and provided an overview of expected near-term milestones.

DelMar management will host a business update conference call and live webcast for investors, analysts and other interested parties on Wednesday, February 17, 2016, at 5:00 pm EST.

"The progress we continued to achieve this quarter for our VAL-083 (*dianhydrogalactitol*) clinical program and the consistent positive data from preclinical studies, along with the recently announced collaboration with University of Texas MD Anderson Cancer Center, not only further validates the promise of VAL-083 as a potential new treatment for chemo-resistant tumors, but also sets the stage for 2016 to be a transformational year for our Company," stated Jeffrey Bacha, Chairman and CEO of DelMar Pharmaceuticals.

RECENT CORPORATE HIGHLIGHTS

- Announced a collaboration with the University of Texas MD Anderson Cancer Center (MD Anderson) to extend and accelerate the clinical development of VAL-083 for glioblastoma multiforme (GBM) patients following first recurrence of the disease. MD Anderson will initiate a new Phase II clinical study with VAL-083 at first recurrence/progression, prior to Avastin ® (bevacizumab) exposure. Eligible patients will have recurrent GBM characterized by a high expression of MGMT, the DNA repair enzyme implicated in drug-resistance and poor patient outcomes following current front-line chemotherapy.
- Completed enrollment of the Phase II expansion cohort for the GBM study at a dose of 40mg/m^2. Confirmed 40mg/m^2 as the maximum tolerated dose (MTD) for advancement into registration directed clinical trials. This optimized dosing regimen may enhance the potential of VAL-083 to impact a patient's tumor as well as to improve patient outcomes.
- Presented interim Phase II data at the 2015 Society for Neuro-Oncology Annual Meeting. A Kaplan Meier survival estimate, based on these preliminary interim data, projects a clinically meaningful survival benefit for refractory GBM patients whose tumors have recurred following both front-line therapy with temozolomide and second-line bevacizumab treatment.
- Presented data supporting VAL-083's potential as a treatment for pediatric brain tumors at the American Association for Cancer Research (AACR) Advances in Pediatric Research Conference. The preclinical and clinical data support advancement of VAL-083 into a clinical study in pediatric patients with recurrent or resistant medulloblastoma (MB) and high grade gliomas (HGGs).

- Presented data indicating the promising potential of VAL-083 as a solution for major unmet needs in the treatment of a variety of cancers, including GBM, non-small cell lung cancer (NSCLC), ovarian cancer and pediatric brain tumors, at the AACR New Horizons in Cancer Research Conference.
- Announced additional data on the unique molecular mechanisms responsible for VAL-083 activity against cancer at the 2015 Canadian Cancer Research Conference. These data suggest that VAL-083's activation of immune response pathways may represent a promising personalized medicine approach in the treatment of cancer.
- Presented positive data on the benefit of VAL-083 in combination with platinum-based chemotherapy for non-small cell lung cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The data demonstrate that VAL-083 retains activity in chemo-resistant NSCLC tumor types and has a super-additive effect in NSCLC when used in combination with platinum-based chemotherapeutic agents.
- Presented positive preclinical data supporting the activity of VAL-083 in treatment-resistant ovarian cancer. The data support VAL-083 as a viable treatment option for patients failing platinum-based chemotherapy and demonstrates a potential benefit in combination with platinum therapy.

"For the first half of 2016 we will focus on accomplishing several actionable milestones that will position DelMar to expand clinical development around VAL-083 and also serve to maximize shareholder value. We believe that DelMar's recent data, combined with historical clinical validation, positions VAL-083 as a superior alternative to currently available chemotherapy for GBM patients whose tumors are characterized by high expression of MGMT. Our goal is nothing short of creating a paradigm-shift in the treatment of this horrific cancer," added Mr. Bacha.

"We anticipate reporting top-line survival data from the Phase II expansion cohort of our refractory GBM clinical trial in the first half of 2016. Based on our observations to date, we believe that we are well positioned to advance VAL-083 into Phase II/III registration clinical trials in refractory GBM during 2016. New non-clinical data reported in 2015 continued to demonstrate VAL-083's unique cytotoxic anti-cancer mechanism, and we anticipate leveraging these data by expanding our clinical development programs around VAL-083 also during 2016," concluded Mr. Bacha.

EXPECTED NEAR-TERM MILESTONES

- Report top-line data from the Phase II study with VAL-083 in refractory GBM in the first half of 2016;
- Engage the U.S. Food and Drug Administration (FDA) regarding the design of a proposed registration-directed Phase II/III clinical trial for VAL-083 in refractory GBM;
- Initiate registration-directed Phase II/III clinical trials for VAL-083 as a new treatment option for refractory GBM in 2016;
- Initiate the Phase II clinical study at MD Anderson with VAL-083 in patients with GBM at first recurrence/progression;
- Initiate clinical studies in newly-diagnosed GBM patients as an alternative to temozolomide in patients with high expression of MGMT;
- Initiate new clinical trials with VAL-083 in refractory NSCLC;

- Continue to pursue pre-clinical research with leading investigators to advance VAL-083 as a potential treatment for other chemo-resistant cancers including ovarian cancer and pediatric medulloblastoma;
- Maximize the value of the VAL-083 pipeline through potential partnership opportunities in high value oncology markets;
- Continue to build the Company's intellectual property portfolio; and
- Continue to implement strategies that enable DelMar to meet qualifications to list its shares on a national stock exchange.

CONFERENCE CALL DETAILS

DelMar plans to host a conference call on Wednesday, February 17, 2016, at 5:00 p.m. EST, to discuss quarterly results and provide a corporate update. For both "listen-only" participants and those who wish to take part in the question and answer portion of the call, the telephone Dial-in Number is (800) 895-1715 (toll-free) or (785) 424-1059 (toll) with Conference ID "DelMar." A link to the webcast and slides will be available on the IR Calendar of the Investors section of the Company's website at www.delmarpharma.com and will be archived for 30 days.

SUMMARY OF FINANCIAL RESULTS FOR THE SECOND QUARTER OF FISCAL YEAR 2016 ENDED DECEMBER 31, 2015

For the three months ended December 31, 2015 the Company reported a net loss of $2,646,690, or a net loss per share of $0.06, compared to a net loss of $619,633, or a net loss per share of $0.02 for the three months ended December 31, 2014 as restated.

FINANCIAL SUMMARY

The following represents selected financial information as of December 31, 2015. The Company's financial information has been prepared in accordance with U.S. GAAP and this selected information should be read in conjunction with DelMar's consolidated financial statements and Management's Discussion and Analysis (MD&A), as filed.

DelMar's financial statements as filed with the U.S. Securities Exchange Commission can be viewed on the company's website at: http://ir.delmarpharma.com/all-sec-filings.

Selected Balance Sheet Data

	December 31, 2015 $	June 30, 2015 $ (as restated)
Cash and cash equivalents	1,957,009	1,754,433
Working capital	1,605,025	1,722,336
Total Assets	2,184,593	2,575,421
Derivative liability	1,352,584	2,364,381
Total stockholders' equity (deficit)	116,729	(821,490)

Selected Statement of Operations Data
For the Three months Ended:

	December 31, 2015 $	December 31, 2014 $ (as restated)
Research and development	789,187	612,169
General and administrative	890,672	656,229
Change in fair value of derivative liability	680,188	(892,326)
Change in fair value of derivative liability due to change in warrant terms	242,400	143,532
Loss on exchange of warrants	–	92,843
Foreign exchange loss	44,253	7,295
Interest income	(10)	(109)
Net loss from operations	2,646,690	619,633
Basic weighted average number of shares outstanding	43,979,516	37,798,183
Basic loss per share	0.06	0.02

About VAL-083
VAL-083 is a "first-in-class," small-molecule chemotherapeutic. In more than 40 Phase I and II clinical studies sponsored by the U.S. National Cancer Institute, VAL-083 demonstrated clinical activity against a range of cancers including lung, brain, cervical, ovarian tumors and leukemia both as a single-agent and in combination with other treatments. VAL-083 is approved in China for the treatment of chronic myelogenous leukemia (CML) and lung cancer, and has received orphan drug designation in Europe and the U.S. for the treatment of malignant gliomas.

DelMar has demonstrated that VAL-083's anti-tumor activity is unaffected by the expression of MGMT, a DNA repair enzyme that is implicated in chemotherapy resistance and poor outcomes in GBM patients following standard front-line treatment with Temodar® (temozolomide).

DelMar recently announced the completion of enrollment in a Phase II clinical trial of VAL-083 in refractory GBM. Patients have been enrolled at five clinical centers in the United States: Mayo Clinic (Rochester, MN); UCSF (San Francisco, CA) and three centers associated with the Sarah Cannon Cancer Research Institute (Nashville, TN, Sarasota, FL and Denver, CO).

In the Phase I dose-escalation portion of the study, VAL-083 was well tolerated at doses up to 40mg/m ^{2} using a regimen of daily x 3 every 21 days. Adverse events were typically mild to moderate; no treatment-related serious adverse events reported at doses up to 40 mg/m^2. Dose limiting toxicity (DLT) defined by thrombocytopenia (low platelet counts) was observed in two of six (33%) of patients at 50 mg/m^2. Generally, DLT-related symptoms resolved rapidly and spontaneously without concomitant treatment, although one patient who presented with hemorrhoids received a platelet transfusion as a precautionary measure.

Sub-group analysis of data from the Phase I dose-escalation portion of the study suggested a dose-dependent and clinically meaningful survival benefit following treatment with VAL-083 in GBM patients whose tumors had progressed following standard treatment with temozolomide, radiotherapy, bevacizumab and a range of salvage therapies.

Patients in a low dose (≤5mg/m^2) sub-group had a median survival of approximately five (5) months versus median survival of approximately nine (9) months for patients in the therapeutic dose (30mg/m^2 & 40mg/m^2) sub-group following initiation of VAL-083 treatment. DelMar reported increased survival at 6, 9 and 12 months following initiation of treatment with VAL-083 in the therapeutic dose sub-group compared to the low dose sub-group.

Further details can be found at http://www.delmarpharma.com/scientific-publications.html.

About DelMar Pharmaceuticals, Inc.
DelMar Pharmaceuticals, Inc. was founded to develop and commercialize new cancer therapies in indications where patients are failing or have become intolerable to modern targeted or biologic treatments. The Company's lead drug in development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme. VAL-083 has been extensively studied by U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients.

For further information, please visit www.delmarpharma.com; or contact DelMar Pharmaceuticals Investor Relations: ir@delmarpharma.com / (604) 629-5989. Connect with the Company on Twitter, LinkedIn, Facebook, and Google+. Investor Relations Counsel: Amato & Partners LLC.

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K.

###

Exhibit 99.2


BUSINESS UPDATE CONFERENCE CALL
February 17, 2016
DelMar
PHARMACEUTICALS
OTCQX: DMPI
Breakthrough Cancer Therapeutics

Forward-Looking Statements

Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Any forward-looking statements contained herein or made in the course of the presentation are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC and the British Columbia Securities Commission, including our current reports on Form 8-K's, Form 10-Q's and most recent Form 10-K. We do not undertake to update these forward-looking statements made by us.

DelMar PHARMACEUTICALS

Conference Call Agenda

2015

A brief review of results and accomplishments

2016

Positioned for a transformational year ahead

DelMar PHARMACEUTICALS

DelMar Pharmaceuticals
Financial Snapshot

- **Cash @ December 31, 2015: $1.9 million**
  - Cash proceeds from warrant exercise Q4'2015: ~$400k
- **Quarterly Burn: ~$1 million**
- **Current operating funds into Q3'2016**
- **Capitalization Dec 31, 2015** ***(proforma)***

Common Shares Outstanding	
DMPI Shares	40.2 m
ExchangeCo	4.0 m
Total outstanding	**44.2 m**
Warrants*	17.9 m
Options	3.6 m
Fully Diluted	**65.7 m**

**Potential funding from "in the money" warrants: $6.2 million*
**3.9 million investor warrants can be called at $0.786/share if stock is >$1.60/share for 20 trading days*

DelMar PHARMACEUTICALS

FY2016
Q2 Financial Results

Selected Balance Sheet Data	December 31, 2015 $	June 30, 2015 $ (as restated)
Cash and cash equivalents	1,957,009	1,754,433
Working capital	1,605,025	1,722,336
Total Assets	2,184,593	2,575,421
Derivative liability	1,352,584	2,364,381
Total stockholders' deficit	116,729	(821,490)

Selected Statement of Operations Data For the Three months Ended:	December 31, 2015 $	December 31, 2014 $ (as restated)
Research and development	789,187	612,169
General and administrative	890,672	656,229
Change in fair value of derivative liability	680,188	(892,326)
Change in fair value of derivative liability due to change in warrant terms	242,400	143,532
Loss on exchange of warrants	–	92,843
Foreign exchange loss (gain)	44,253	7,295
Interest income	(10)	(109)
Net loss from operations	2,646,690	619,633
Basic weighted average number of shares outstanding	43,979,516	37,798,183
Basic loss per share	0.06	0.02

DelMar PHARMACEUTICALS

2015 Accomplishments Position DMPI for Strong Momentum in 2016

Significant progress in Phase I/II VAL-083 refractory GBM clinical trial

- ✓ Determined MTD and dosing regimen for advanced clinical trials
- ✓ Completed enrollment in Phase II expansion cohort
- ✓ Reported interim data supporting a clinically meaningful survival benefit in post-Avastin refractory GBM

Promising pre-clinical data support VAL-083 for major and orphan chemo-resistant cancers

VAL-083 Target Markets: 2014 WW Revenue

Non-small cell lung cancer	*$6.8 B*	Ovarian cancer	*>$200 M*
Glioma	*$1.0 B*	Pediatric medulloblastoma	*Orphan*

Source: Evaluate Pharma

Clinical and regulatory advancements of VAL-083 in refractory GBM ensure transition into Phase II/III registration-directed studies in 2016

DelMar PHARMACEUTICALS

VAL-083: DelMar's Initial Product Candidate Leveraging Historical Clinical Data with Modern Science

- **Historical data from NCI-sponsored research**
  - First-in-class small molecule chemotherapy
  - >40 NCI-sponsored clinical trials demonstrate clinical activity against multiple tumor types
    - CNS & Solid Tumors
  - Readily crosses blood-brain-barrier
  - Safety database: >1000 patients
    - Safety & toxicity
    - Pharmacokinetics



$C_6H_{10}O_4$ MW=146

DelMar PHARMACEUTICALS

VAL-083: DelMar's Initial Product Candidate
Leveraging Historical Clinical Data with Modern Science

Reduce Cost, Risk & Time in Drug Discovery & Development



DelMar PHARMACEUTICALS

Growing Patent Portfolio: Robust Intellectual Property Protection

- **Eight separate patent families with multiple patents**
  - Claims include use, manufacturing, analytical, mechanism and composition claims
- **Five US patents and four international patents issued to date**
  - Patent protection into 2033 in US
- **90 additional patents + 4 provisional applications pending**
- **VAL-083 granted orphan drug designation in US & EU**
  - Seven years market exclusivity after approval in US
  - 10 years market exclusivity after approval in Europe

DelMar PHARMACEUTICALS

VAL-083: Unique Cytotoxic Mechanism Supports Multiple Target Indications



Summary of VAL-083 Research Presented in 2015:

- *Bi-functional alkylator*
- *DNA Cross-links @ N7 position of guanine*
- *Cell cycle arrest in S/G2*
- *Activity not dependent on WT-p53*
- *Double strand breaks during DNA-replication*

New Understanding of Mechanism:

- *Defines unmet medical need targets*
- *Establishes biomarkers for patient selection*
- *Defines combination therapy & partnering opportunities*

DelMar PHARMACEUTICALS

VAL-083: Building a Pipeline to Provide the Right Drug to the Right Patient at the Right Time



DelMar PHARMACEUTICALS

VAL-083's First Opportunity: GBM

- Glioblastoma multiforme (GBM)
  - 15,000 patients diagnosed each year in US
  - Median survival: ~15 months from diagnosis
- 2/3 of newly diagnosed GBM patients exhibit high-expression of MGMT – a natural DNA repair enzyme causing resistance to currently available chemotherapy
- **VAL-083 is active independent of MGMT-mediated resistance**
- MGMT measurement after diagnosis is standard of care and establishes a biomarker for patient selection
- Prior NCI-sponsored trials demonstrate clinical activity against GBM

DelMar PHARMACEUTICALS

VAL-083's First Opportunity: GBM

Current Treatment Paradigm

Diagnosis

↓

Surgical "debulking"

↓

Temodar® + Radiation

↓ ***2/3 of patients fail***

Avastin®

↓ ***No impact on survival***

palliative or supportive care

New Paradigm Vision for VAL-083

Diagnosis

↓

Surgical "debulking"

↓

MGMT Assessment

↓

2/3 **VAL-083** + Radiotherapy

1/3 Temodar® + Radiotherapy

plus … potential for Immunotherapy, Anti-VEGF, EFT

DelMar PHARMACEUTICALS

VAL-083 Post Avastin Refractory GBM Ongoing Phase I/II Clinical Trial

Current Treatment Paradigm

Diagnosis

↓

Surgical "debulking"

↓

Temodar® + Radiation

↓

Avastin®

↓

VAL-083 initial clinical trial
Phase II

Clinicaltrials.gov Identifier: NCT01478178	

Design	• Single-arm, open label
	  • *Phase I: Dose escalation*
	  • *Phase II: Expansion cohort at MTD*

Summary Inclusion Criteria	• GBM recurrent following surgery, temozolomide + radiation & bevacizumab
Treatment Intervention	• VAL-083 (single agent)
Study Goals	• Determine dosing regimen for advanced clinical trials • Assess patient outcomes
Fully Enrolled at Five Clinical Sites in USA	• UC San Francisco *(San Francisco, CA)* • Mayo Clinic *(Rochester, MN)* • Sarah Cannon Cancer Research Institute *(3 sites: Nashville; Denver; Sarasota)*

DelMar PHARMACEUTICALS

VAL-083 Post Avastin Refractory GBM
Ongoing Phase I/II Clinical Trial

- **Phase II expansion cohort fully enrolled**
  - *Rapid enrollment in ~3 ½ months*
  - *20 patients have been enrolled at assumed therapeutic doses (≥30mg/m^2)*
- **Goal #1: *40mg/m^2 is a well tolerated dose suitable for advancement to registration-directed trials***
  - *Safety observations in the Phase II expansion cohort to date are consistent with Phase I dose-escalation cohort*
- **Goal #2: Assess Patient Outcomes**
  - *Preliminary Kaplan Meier estimate consistent with Phase I observation: Predicted OS ≥9 months*
  - *Expect top-line median OS observation in H1-2016*

DelMar PHARMACEUTICALS

Current VAL-083 Post Avastin GBM Clinical Trial Phase II Interim Update (SNO 2015)

VAL-083: observed dose-response trend supports clinically meaningful improvement survival outcomes in post-Avastin GBM



*Iwomoto (2009)
**DelMar ASCO & SNO (2015)

DelMar PHARMACEUTICALS

VAL-083 Refractory GBM
Clear Pathway to Commercialization

- **H1-2016**
  - Top-line survival data from current Phase II trial
  - FDA guidance meeting
- **H2-2016**
  - Initiate registration-directed Phase III clinical trial

Proposed Phase III Design to be Discussed with FDA

Controlled, randomized trial

Randomization 1:1 (VAL-083 vs. supportive chemotherapy)

Primary Endpoint: Overall Survival

Statistical Illustration *(for illustration purposes only)*

80% power; 5% significance

Overall Survival (months)		Survival Benefit	Patients per Arm	Total Enrollment
control	VAL-083			
5	9	4 months	36	72
5	8	3 months	63	126

DelMar PHARMACEUTICALS

VAL-083's First Opportunity: GBM 2016 Clinical Plan … Implementing the Paradigm Shift



DelMar PHARMACEUTICALS

VAL-083 GBM
Two New Clinical Trials to Launch H1-2016

H1-2016	1 - FRONT-LINE (Newly Diagnosed)	2 - FIRST RECURRENCE
Design	• Single-arm, open label Phase II	• Randomized, open label Phase II
Summary Inclusion Criteria	• GBM newly diagnosed, unmethylated MGMT promoter	• First recurrence following TMZ failure unmethylated MGMT promoter
Treatment Intervention	• VAL-083 (single agent) + radiotherapy followed by maintenance with VAL-083 *(i.e. Stupp w/ VAL-083)*	• VAL-083 (single agent) - vs - **1:1 randomization** • CCNU (single agent)
Study Goal	• Confirm safety in combination with radiotherapy • Assess patient outcomes (PFS and OS) • Lead-in for global randomized trial	• Assess patient outcomes (PFS and OS) • Lead-in for Phase III
Initial Clinical Site	• Sun-Yat Sen University (China) ➢ *Funded by DelMar manufacturing partner Guangxi Wuzhou Pharma*	• UT MD Anderson Cancer Center

DelMar PHARMACEUTICALS

VAL-083's First Opportunity: GBM



VAL-083's distinct anti-cancer mechanism

- ✓ Unlocks potential to overcome chemo-resistance and surpass standard of care
- ✓ Would create a new survival paradigm for the first time in decades
- ✓ Lays the foundation for global development to address *>$1 billion* market opportunity as chemotherapy of choice in the treatment of GBM

DelMar PHARMACEUTICALS

Expanding Our Clinical Portfolio: VAL-083 in NSCLC

- **Global partnering opportunity**
- **Lung cancer is the leading cause of cancer death world-wide**
- **Non-small cell lung cancer (NSCLC)**
  - Current drugs represent >$6 billion in world wide annual sales
  - Overall 5 year NSCLC survival rate: 15%
  - CNS metastases – a leading cause of NSCLC mortality
- **Existing and new data support potential of VAL-083 in NSCLC**
- **VAL-083 is approved in China for the treatment of lung cancer**
- **Phase IV NSCLC trial to be initiated in 2016**
  - Funded via DelMar collaboration with Chinese manufacturer
  - Study Goals:
    - Provide biomarker-driven guidance to treating physicians under existing approval in China
    - Phase II proof-of-concept to support global development in biomarker circumscribed subsets of NSCLC where there is unmet medial need

DelMar PHARMACEUTICALS

Building Our Pipeline: VAL-083 in Ovarian Cancer & Pediatric Brain Cancer

Ovarian Cancer

- Pre-clinical and historical clinical data support potential of VAL-083 in Ovarian Cancer
  - *Data presented at AACR Advances in Ovarian Cancer*

Pediatric Brain Cancer

- Pre-clinical and historical clinical data support potential of VAL-083 in medulloblastoma and other pediatric brain tumors
  - *Data presented at AACR Advances in Pediatric Cancer Research*
- Clinical strategies under development
- Potential global partnering opportunities

DelMar PHARMACEUTICALS

VAL-083 Clinical Development: Timelines & Milestones

	2015	2016		2017-18
GBM *(refractory)*				
Phase I: Define MTD	✓ COMPLETE			
Phase II				
Complete Enrollment	✓ COMPLETE			
Interim Data @ SNO2015	✓ COMPLETE			
Top-line OS Data		**H1-2016**		
FDA Guidance Meeting		**H1-2016**		
Initiate Phase III			**H2-2016**	
NDA-Approval				**2017-18**
Launch				**2018**
GBM *(newly diagnosed MGMT-unmethylated)*				
Phase II Initiation		**H1-2016**		
GBM *(first recurrence MGMT-unmethylated)*				
Phase II Initiation		**H1-2016**		
NSCLC				
Phase IV China Initiation		**H1-2016**		
Additional Clinical Studies				
Other solid tumors				**2017-18**

DelMar PHARMACEUTICALS

DelMar: Positioned for 2016 to be a Transformational Year

Actionable Milestones in the First Half of 2016

- Phase II Top-line Data: Refractory GBM
- New Clinical Trial: Front-line GBM
- New Clinical Trial: NSCLC
- FDA Guidance Meeting in preparation for Phase III clinical trials in refractory GBM
- U.S. National Exchange Listing for DMPI Shares *(NYSE-MKT or NASDAQ)*

- **Positioned to initiate registration-directed clinical trials in refractory GBM during 2016**
- **Pipeline development research collaboration with leading investigators at UCSF, Mayo Clinic and MD Anderson Cancer Center**
- **Potential to capitalize on global partnering opportunities**
- **Working in earnest to up-list to a National Exchange**

DelMar PHARMACEUTICALS

Value Indicators Suggest Potential for Significant Upside for DMPI

Company	Ticker	Development Stage	Market Cap*
Companies Developing GBM Programs			
Celldex therapeutics	CLDX	Phase 3	**$1.26B**
Northwest Biotherapeutics	NWBO	Phase 3	**$220.4M**
CytRx Corporation	CYTR	Phase 2	**$136.2M**
Public Companies Developing Late-stage Oncology Programs			
Exelixis	EXEL	Phase 3	**$1.11B**
Progenics Pharmaceuticals	PGNX	Phase 3	**$344.8M**
Puma Biotechnology	PBYI	Phase 3	**$1.91B**
TG Therapeutics	TGTX	Phase 3	**$455.83M**

**Market Cap as of January 8, 2016*

DelMar PHARMACEUTICALS

DelMar Pharmaceuticals Investment Opportunity

- ✓ **VAL-083**
  - ❖ "First-in-class" small molecule chemotherapy
    - ❖ Unique anti-cancer mechanism overcomes chemo-resistance
    - ❖ NCI demonstrated clinical activity across a range of cancers
  - ❖ Promising interim outcomes data in refractory GBM clinical trial
    - ❖ Advancing to "late-stage" clinical development in 2016
  - ❖ Pipeline expansion opportunities in high value oncology markets
  - ❖ Robust IP protection from newly issued patents
  - ❖ Orphan drug designation in US and EU
- ✓ **Experienced Team with History of Success**
- ✓ **Expected Near-term Up-listing Opportunity**
- ✓ **Transformational Near-term Catalysts**

DelMar PHARMACEUTICALS

Q&A


OTCQX:DMPI
Corporate Headquarters
Suite 720 – 999 W. Broadway
Vancouver, British Columbia
Canada V5Z 1K5
Clinical Operations
3475 Edison Way, Suite R
Menlo Park, California 94025
USA
www.delmarpharma.com
DelMar
PHARMACEUTICALS
Breakthrough Cancer Therapeutics